

**Product Name:** SK 216

**Catalog No.:** 6187


**Batch No.:** 1

CAS Number: 654080-03-2

IUPAC Name: 2-[5-[[6-[5-(1,1-Dimethylethyl)-2-benzoxazolyl]-2-naphthalenyl]oxy]pentyl]propanedioic acid disodium salt

**1. PHYSICAL AND CHEMICAL PROPERTIES**

**Batch Molecular Formula:** C<sub>29</sub>H<sub>29</sub>NO<sub>6</sub>Na<sub>2</sub>·¼H<sub>2</sub>O  
**Batch Molecular Weight:** 538.02  
**Physical Appearance:** White solid  
**Solubility:** water to 5 mM with gentle warming  
**Storage:** Desiccate at RT  
**Batch Molecular Structure:**



**2. ANALYTICAL DATA**

**HPLC:** Shows 99.6% purity  
**<sup>1</sup>H NMR:** Consistent with structure  
**Mass Spectrum:** Consistent with structure

**Microanalysis:**

	Carbon	Hydrogen	Nitrogen
Theoretical	64.74	5.53	2.6
Found	64.81	5.51	2.37

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**Product Name:** SK 216

**Catalog No.:** 6187

**Batch No.:** 1

CAS Number: 654080-03-2

IUPAC Name: 2-[5-[[6-[5-(1,1-Dimethylethyl)-2-benzoxazolyl]-2-naphthalenyl]oxy]pentyl]propanedioic acid disodium salt

**Description:**

Plasminogen activator inhibitor-1 (PAI-1) inhibitor. Inhibits VEGF-induced migration and tube formation in HUVECs. Also attenuates TGF- $\beta$  dependent epithelial-mesenchymal transition and fibroblast to myofibroblast differentiation in vitro. Reduces size and weight of subcutaneous tumors, and inhibits metastasis and angiogenesis in vivo. Reduces bleomycin-induced pulmonary fibrosis in vivo. Orally bioavailable.

**Physical and Chemical Properties:**


Batch Molecular Formula: C<sub>29</sub>H<sub>29</sub>NO<sub>6</sub>Na<sub>2</sub>· $\frac{1}{4}$ H<sub>2</sub>O

Batch Molecular Weight: 538.02

Physical Appearance: White solid

**Minimum Purity:** >98%

**Batch Molecular Structure:**



**Storage:** Desiccate at RT

**Solubility & Usage Info:**

water to 5 mM with gentle warming

**Stability and Solubility Advice:**

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

**SOLIDS:** Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

**SOLUTIONS:** We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

**References:**

**Omori et al** (2016) Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor- $\beta$ -dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. *PLoS One*. **11** e0148969. PMID: 26859294.

**Takayama et al** (2016) Inhibition of PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in malignant pleural mesothelioma. *Cancer Res*. **76** 3285. PMID: 27197170.

**Masuda et al** (2013) SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. *Mol.Cancer Ther*. **12** 2378. PMID: 23990114.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**bio-techne.com**

info@bio-techne.com

techsupport@bio-techne.com

**North America**

Tel: (800) 343 7475

**China**

info.cn@bio-techne.com

Tel: +86 (21) 52380373

**Europe Middle East Africa**

Tel: +44 (0)1235 529449

**Rest of World**

www.tocris.com/distributors

Tel:+1 612 379 2956